Effects of adrenomedullin in steroid-resistant patients with ulcerative colitis: randomized, double-blind, placebo-controlled phase 2a clinical trial

niversity of Miyazaki0 个研究点目标入组 28 人开始时间: 2020年4月10日最近更新: 2023年10月17日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 28

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Despite the limited number of patients in this double-blind randomized trial, we observed the successful complete remission at 8 weeks in patients with steroid-resistant UC receiving a high dose of AM. Hence, AM could serve as candidate potent therapeutic agent for complete remission in refractory UC.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 <= 75age old（—）
性别: All

入选标准

•patients with steroid-resistant ulcerative colitis

排除标准

•Patient using biologics
•Patient with fulminant ulcerative colitis (UC)
•Patient need early operation for UC
•Patient with precancerous lesion(s) in the colon
•Patient with active infection
•Patient with severe complication(s)
•Patient with malignancy or past history of malignancy
•Pregnant woman

研究者

发起方

niversity of Miyazaki

相似试验

已完成

2 期

Phase 2a clinical trial for Crohn disease using adrenomedulliCrohn disease

JPRN-jRCT2080223890niversity of Miyazaki24

撤回

4 期

No Resistance After Long Term Treatment SERETIDEAsthma

NCT00456313GlaxoSmithKline

已完成

3 期

Rituximab for Idiopathic Nephrotic SyndromeIdiopathic Nephrotic Syndrome

NCT04494438Istituto Giannina Gaslini30

已完成

2 期

Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized StudyAdult-Onset Still's Disease

NCT01033656University of Helsinki23

已完成

4 期

CMR to Assess Fibrosis in Cardiomyopathy Using EplerenoneCardiomyopathy

NCT00401856Royal Brompton & Harefield NHS Foundation Trust42